Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

KPTI

Karyopharm Therapeutics Inc.

Pharmaceutical Preparations · SIC 2834CIK 1503802Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$146.0M
Net Income FY2025
$(196.0M)
EPS (Basic, as reported)
—
Net Margin FY2025
-134.2%
ROE FY2025
66.9%
Total Equity
$(293.0M)
Shares Out
23M
Business description

Karyopharm Therapeutics Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 146
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue023041108210157146145146
Research & development(87)(107)(161)(122)(151)(161)(149)(139)(143)(126)
Selling, general & administrative—(25)(49)(105)(126)(144)(145)(132)(115)(105)
General & administrative(24)(25)(49)———————
Total operating expenses(111)(132)(210)(230)(280)(308)(299)(276)(265)(237)
Operating income(111)(131)(180)(189)(172)(98)(142)(130)(119)(91)
Interest expense——(2)(16)(27)(26)(25)(24)(37)(46)
Interest & investment income12453121173
Other income (expense), net122(10)(24)(26)(23)(13)43(105)
Pre-tax income(109)(129)(178)(200)(196)(124)(165)(143)(76)(196)
Income tax expense0000000000
Net income(110)(129)(178)(200)(196)(124)(165)(143)(76)(196)
EPS — basic————($2.72)($1.65)($2.02)—($0.63)—
EPS — diluted————($2.72)($1.65)($2.02)—($0.93)—
Shares outstanding — basic (M)————727582000
Shares outstanding — diluted (M)————727582000

Showing the latest 10 of 17 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.